NCT00103779已完成1 期
A Phase I, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Non-Hodgkin's Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Seagen Inc.
- 入组人数
- 50
- 试验地点
- 5
- 主要终点
- Adverse events and lab abnormalities.
研究概览
简要总结
This is an open-label, multi-dose, Phase I, dose escalation study to define the safety profile and preliminary anti-tumor activity of SGN-40 in patients with refractory or recurrent non-Hodgkin B-cell lymphomas.
详细描述
A minimum of 3 patients will be entered into each dose-level cohort for 5 weeks. A dose-escalation schema will be employed in cohorts. The initial dose starts at 1 mg/kg on Day 1 and 4 followed by 2mg/kg on Day 8. Dose escalation will occur on weeks 3-5 with a maximum weekly dose of 8 mg/kg. Patients who meet criteria of at least partial response will be eligible for additional 4 weekly doses at highest dose tolerated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have a histological diagnosis of B cell non-Hodgkin's lymphoma, including diffuse large B-cell, mantle cell, follicular, small lymphocytic, and marginal zone lymphoma by the World Health Organization criteria.
- •Patients must have an archived paraffin or fresh tumor specimen available for immunohistologic evaluation of CD40, CD20, & CD79a.
- •Patients must have relapsed lymphoma and must have failed frontline chemotherapy.
- •Patients who have not received autologous stem cell transplant must have refused or be ineligible for it.
- •Patients must have completed radiotherapy, chemotherapy, and/or treatment with investigational anti-cancer agents 4 weeks prior to registration. Patients must have completed any monoclonal antibody treatment, including rituximab, 6 months prior to registration.
- •Patients must have completed autologous bone marrow transplant 4 months prior to registration.
- •Patient must have at least one site of measurable disease defined by unidimensional lesion ≥ 2 cm by conventional CT scan.
- •Patients must have an ECOG performance status ≤ 2 and a life expectancy > 3 months.
- •Patients must have the following required baseline laboratory data:
- •Platelet count ≥ 75,000/mm3,
- •Hemoglobin ≥ 9.0 g/dL,
- •Absolute neutrophil count ≥ 1,250/mm3,
- •ALT/AST ≤ 2.5 times ULN,
- •Total bilirubin ≤ 1.5 times ULN,
- •Creatinine < 1.5 mg/dL,
- •Females of childbearing potential must have a negative serum β-hCG pregnancy test result within 3 days prior to the first dose of SGN-40 and must agree to use an effective contraceptive method during the course of the study and for 6 months following the last dose of study drug.
- •If a deep venous thrombosis or other vascular even has required medical or surgical intervention in the past year, patients must either be on stable dose of anticoagulant therapy for at least 3 weeks or have completed anticoagulant therapy at least 3 months prior to registration with radiographic confirmation that thrombosis is resolved.
- •Patients must be at least 18 years of age.
- •Patients must be available for periodic blood sampling, study-related assessments and management of toxicity at the treating institution.
排除标准
- •Patients with history or clinical evidence of leptomeningeal or central nervous system (CNS) lymphoma.
- •Patients with a documented history within 6 months of registration of a cerebral vascular event, myocardial infarction, deep venous thrombosis or other vascular event that has required medical or surgical intervention. Patients must have completed anticoagulant therapy at least 3 months prior to registration. Prophylactic anticoagulant therapy for indwelling catheters is acceptable.
- •Patients who have received an allogeneic stem cell transplant.
- •Patients who have had major surgery within 4 weeks prior to registration.
- •Patients with a known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation.
- •Patients with a history of another primary malignancy that has not been in remission for at least 5 years (non-melanoma skin cancer and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on PAP smear are exempt from the five year limit).
- •Patients with any active systemic viral, bacterial, or fungal infection within four weeks prior to registration.
- •Patients with known positivity for HIV, hepatitis B or hepatitis C infection.
- •Patients with a history of significant chronic or recurrent infections requiring treatment.
- •Patients with a history of migraines or severe headaches requiring medical therapy within 12 months of enrollment.
- •Patients on systemic steroids who have not been on a stable daily dose (not exceeding 10 mg prednisone or equivalent) during 4 weeks prior to the first dose of SGN
- •Patients who are pregnant or breastfeeding.
- •Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment.
- •Patients with dementia or altered mental status that would preclude the understanding and/or rendering of informed consent.
研究组 & 干预措施
1
Experimental
干预措施: SGN-40 (anti-huCD40 mAb) (Drug)
结局指标
主要结局
Adverse events and lab abnormalities.
次要结局
未报告次要终点
研究者
研究点 (5)
Loading locations...
相似试验
已完成
1 期
A Safety Study in Patients With Chronic Lymphocytic LeukemiaLeukemia, Lymphocytic, ChronicNCT00283101Seagen Inc.12
已完成
1 期
Study of SGN-40 in Patients With Refractory or Recurrent Multiple MyelomaMultiple MyelomaNCT00079716Seagen Inc.44
已完成
1 期
Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple MyelomaMultiple MyelomaNCT00525447Seagen Inc.36
已完成
2 期
Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell LymphomaLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinNCT00435916Seagen Inc.46
终止
1 期
Safety Study of SEA-CD40 in Cancer PatientsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellHodgkin DiseaseLymphoma, B-CellLymphoma, FollicularLymphoma, Large B-Cell, DiffuseNeoplasm MetastasisMelanomaNeoplasms, Head and NeckNeoplasms, Squamous CellNon-Small Cell Lung Cancer MetastaticNon-small Cell CarcinomaSquamous Cell CancerSquamous Cell Carcinoma of the Head and NeckNon-Small Cell Lung CancerSquamous Cell NeoplasmLymphoma, Non-HodgkinPancreatic AdenocarcinomaLymphomaSquamous Cell CarcinomaNCT02376699Seagen Inc.159